GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (FRA:MR4) » Definitions » Gross Profit

Meridian Bioscience (FRA:MR4) Gross Profit : €174.8 Mil (TTM As of Sep. 2022)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Gross Profit?

Meridian Bioscience's gross profit for the three months ended in Sep. 2022 was €34.3 Mil. Meridian Bioscience's gross profit for the trailing twelve months (TTM) ended in Sep. 2022 was €174.8 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Meridian Bioscience's gross profit for the three months ended in Sep. 2022 was €34.3 Mil. Meridian Bioscience's Revenue for the three months ended in Sep. 2022 was €66.3 Mil. Therefore, Meridian Bioscience's Gross Margin % for the quarter that ended in Sep. 2022 was 51.76%.

Meridian Bioscience had a gross margin of 51.76% for the quarter that ended in Sep. 2022 => Durable competitive advantage


Meridian Bioscience Gross Profit Historical Data

The historical data trend for Meridian Bioscience's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Gross Profit Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.30 107.81 132.66 170.98 190.24

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.01 43.51 62.18 34.75 34.33

Competitive Comparison of Meridian Bioscience's Gross Profit

For the Diagnostics & Research subindustry, Meridian Bioscience's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meridian Bioscience's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Gross Profit distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Gross Profit falls into.



Meridian Bioscience Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Meridian Bioscience's Gross Profit for the fiscal year that ended in Sep. 2022 is calculated as

Gross Profit (A: Sep. 2022 )=Revenue - Cost of Goods Sold
=336.348 - 146.108
=190.2

Meridian Bioscience's Gross Profit for the quarter that ended in Sep. 2022 is calculated as

Gross Profit (Q: Sep. 2022 )=Revenue - Cost of Goods Sold
=66.332 - 32
=34.3

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €174.8 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Meridian Bioscience's Gross Margin % for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=34.3 / 66.332
=51.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Meridian Bioscience  (FRA:MR4) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Meridian Bioscience had a gross margin of 51.76% for the quarter that ended in Sep. 2022 => Durable competitive advantage


Meridian Bioscience Gross Profit Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (FRA:MR4) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Meridian Bioscience (FRA:MR4) Headlines

No Headlines